[SCHEDULE 13G/A] Enlivex Therapeutics Ltd. SEC Filing
Armistice Capital, LLC and Steven Boyd filed a Schedule 13G/A reporting shared beneficial ownership of 1,178,389 ordinary shares of Enlivex Therapeutics Ltd. (CUSIP 05280R100), representing 4.99% of the class. Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., states it exercises voting and investment power over the shares held by the Master Fund; Mr. Boyd, as managing member, is similarly reported. The filing affirms the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Armistice Capital, LLC e Steven Boyd hanno presentato un Schedule 13G/A dichiarando la titolarit脿 condivisa di 1.178.389 azioni ordinarie di Enlivex Therapeutics Ltd. (CUSIP 05280R100), corrispondenti al 4.99% della classe. Armistice Capital, in qualit脿 di gestore degli investimenti per Armistice Capital Master Fund Ltd., dichiara di esercitare i poteri di voto e di investimento sulle azioni detenute dal Master Fund; analogamente, il sig. Boyd 猫 indicato come membro direttivo. La comunicazione specifica che le partecipazioni sono state acquisite e sono detenute nell'ordinario corso dell'attivit脿 e non con l'intento di modificare o influenzare il controllo.
Armistice Capital, LLC y Steven Boyd presentaron un Schedule 13G/A informando la propiedad beneficiaria compartida de 1.178.389 acciones ordinarias de Enlivex Therapeutics Ltd. (CUSIP 05280R100), que representan el 4.99% de la clase. Armistice Capital, como gestor de inversiones del Armistice Capital Master Fund Ltd., declara ejercer el poder de voto y de inversi贸n sobre las acciones en manos del Master Fund; el Sr. Boyd figura de forma similar como miembro gerente. La presentaci贸n confirma que las participaciones fueron adquiridas y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control.
Armistice Capital, LLC鞕� Steven Boyd電� Schedule 13G/A毳� 鞝滌稖頃橃棳 Enlivex Therapeutics Ltd.鞚� 氤错喌欤� 1,178,389欤�(CUSIP 05280R100)鞐� 雽�頃� 瓿惦彊 鞁れ唽鞙犽ゼ 氤搓碃頄堨溂氅�, 鞚措姅 頃措嫻 膦呺鞚� 4.99%鞐� 頃措嫻頃╇媹雼�. Armistice Capital鞚� Armistice Capital Master Fund Ltd.鞚� 韴瀽 毵る媹鞝�搿滌劀 毵堨姢韯� 韼�霌滉皜 氤挫湢頃� 欤检嫕鞐� 雽�頃� 鞚橁舶甓� 氚� 韴瀽 甓岉暅鞚� 頄夓偓頃滊嫟瓿� 氚濏様瓿�, Boyd 鞌姅 毵る媹歆� 氅る矂搿滌劀 鞙犾偓頃橁矊 氤搓碃霅橃棃鞀惦媹雼�. 鞝滌稖 靹滊電� 頃措嫻 氤挫湢臧� 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 旆摑路氤挫湢霅� 瓴冹澊氅� 歆�氚瓣秾 氤�瓴届澊雮� 鞓來枼霠レ潉 頄夓偓頃� 氇╈爜鞙茧 頃� 瓴冹澊 鞎勲嫎鞚� 頇曥澑頃╇媹雼�.
Armistice Capital, LLC et Steven Boyd ont d茅pos茅 un Schedule 13G/A d茅clarant la propri茅t茅 b茅n茅ficiaire conjointe de 1 178 389 actions ordinaires d'Enlivex Therapeutics Ltd. (CUSIP 05280R100), repr茅sentant 4.99% de la cat茅gorie. Armistice Capital, en tant que gestionnaire d'investissement d'Armistice Capital Master Fund Ltd., indique exercer les pouvoirs de vote et d'investissement sur les actions d茅tenues par le Master Fund ; M. Boyd est de m锚me signal茅 en tant que membre dirigeant. Le d茅p么t pr茅cise que les d茅tentions ont 茅t茅 acquises et sont d茅tenues dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le.
Armistice Capital, LLC und Steven Boyd reichten ein Schedule 13G/A ein und meldeten gemeinsames wirtschaftliches Eigentum an 1.178.389 Stammaktien der Enlivex Therapeutics Ltd. (CUSIP 05280R100), was 4.99% der Klasse entspricht. Armistice Capital gibt an, als Investmentmanager des Armistice Capital Master Fund Ltd. die Stimm- und Anlagebefugnis 眉ber die vom Master Fund gehaltenen Aktien auszu眉ben; Herr Boyd wird in 盲hnlicher Funktion als gesch盲ftsf眉hrendes Mitglied angegeben. Die Meldung best盲tigt, dass die Beteiligungen im 眉blichen Gesch盲ftsbetrieb erworben und gehalten werden und nicht mit dem Ziel, die Kontrolle zu 盲ndern oder zu beeinflussen.
- None.
- None.
Insights
TL;DR: Reporting persons disclose a 4.99% position, indicating a non-control stake below the 5% reporting threshold for greater scrutiny.
The Schedule 13G/A shows a 4.99% beneficial position (1,178,389 shares) held via an institutional master fund with shared voting and dispositive power. This level of ownership is under common 5% thresholds that often trigger more active monitoring or 13D filings; the statement claims ordinary-course holdings and absence of intent to influence control. For investors, this is a transparent institutional disclosure without indications of activism or control changes.
TL;DR: Ownership structured through an investment manager and master fund with shared voting power, disclosed as non-control and ordinary-course holdings.
Armistice Capital鈥檚 role as investment manager to the Master Fund, and Mr. Boyd鈥檚 role as managing member, create shared voting/dispositive reporting despite the Master Fund disclaiming direct beneficial ownership due to the management agreement. The certification language and joint filing indicate compliance with Schedule 13G reporting rules; there are no statements in the filing suggesting coordinated group action or plans to change board control.
Armistice Capital, LLC e Steven Boyd hanno presentato un Schedule 13G/A dichiarando la titolarit脿 condivisa di 1.178.389 azioni ordinarie di Enlivex Therapeutics Ltd. (CUSIP 05280R100), corrispondenti al 4.99% della classe. Armistice Capital, in qualit脿 di gestore degli investimenti per Armistice Capital Master Fund Ltd., dichiara di esercitare i poteri di voto e di investimento sulle azioni detenute dal Master Fund; analogamente, il sig. Boyd 猫 indicato come membro direttivo. La comunicazione specifica che le partecipazioni sono state acquisite e sono detenute nell'ordinario corso dell'attivit脿 e non con l'intento di modificare o influenzare il controllo.
Armistice Capital, LLC y Steven Boyd presentaron un Schedule 13G/A informando la propiedad beneficiaria compartida de 1.178.389 acciones ordinarias de Enlivex Therapeutics Ltd. (CUSIP 05280R100), que representan el 4.99% de la clase. Armistice Capital, como gestor de inversiones del Armistice Capital Master Fund Ltd., declara ejercer el poder de voto y de inversi贸n sobre las acciones en manos del Master Fund; el Sr. Boyd figura de forma similar como miembro gerente. La presentaci贸n confirma que las participaciones fueron adquiridas y se mantienen en el curso ordinario del negocio y no con el prop贸sito de cambiar o influir en el control.
Armistice Capital, LLC鞕� Steven Boyd電� Schedule 13G/A毳� 鞝滌稖頃橃棳 Enlivex Therapeutics Ltd.鞚� 氤错喌欤� 1,178,389欤�(CUSIP 05280R100)鞐� 雽�頃� 瓿惦彊 鞁れ唽鞙犽ゼ 氤搓碃頄堨溂氅�, 鞚措姅 頃措嫻 膦呺鞚� 4.99%鞐� 頃措嫻頃╇媹雼�. Armistice Capital鞚� Armistice Capital Master Fund Ltd.鞚� 韴瀽 毵る媹鞝�搿滌劀 毵堨姢韯� 韼�霌滉皜 氤挫湢頃� 欤检嫕鞐� 雽�頃� 鞚橁舶甓� 氚� 韴瀽 甓岉暅鞚� 頄夓偓頃滊嫟瓿� 氚濏様瓿�, Boyd 鞌姅 毵る媹歆� 氅る矂搿滌劀 鞙犾偓頃橁矊 氤搓碃霅橃棃鞀惦媹雼�. 鞝滌稖 靹滊電� 頃措嫻 氤挫湢臧� 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 旆摑路氤挫湢霅� 瓴冹澊氅� 歆�氚瓣秾 氤�瓴届澊雮� 鞓來枼霠レ潉 頄夓偓頃� 氇╈爜鞙茧 頃� 瓴冹澊 鞎勲嫎鞚� 頇曥澑頃╇媹雼�.
Armistice Capital, LLC et Steven Boyd ont d茅pos茅 un Schedule 13G/A d茅clarant la propri茅t茅 b茅n茅ficiaire conjointe de 1 178 389 actions ordinaires d'Enlivex Therapeutics Ltd. (CUSIP 05280R100), repr茅sentant 4.99% de la cat茅gorie. Armistice Capital, en tant que gestionnaire d'investissement d'Armistice Capital Master Fund Ltd., indique exercer les pouvoirs de vote et d'investissement sur les actions d茅tenues par le Master Fund ; M. Boyd est de m锚me signal茅 en tant que membre dirigeant. Le d茅p么t pr茅cise que les d茅tentions ont 茅t茅 acquises et sont d茅tenues dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contr么le.
Armistice Capital, LLC und Steven Boyd reichten ein Schedule 13G/A ein und meldeten gemeinsames wirtschaftliches Eigentum an 1.178.389 Stammaktien der Enlivex Therapeutics Ltd. (CUSIP 05280R100), was 4.99% der Klasse entspricht. Armistice Capital gibt an, als Investmentmanager des Armistice Capital Master Fund Ltd. die Stimm- und Anlagebefugnis 眉ber die vom Master Fund gehaltenen Aktien auszu眉ben; Herr Boyd wird in 盲hnlicher Funktion als gesch盲ftsf眉hrendes Mitglied angegeben. Die Meldung best盲tigt, dass die Beteiligungen im 眉blichen Gesch盲ftsbetrieb erworben und gehalten werden und nicht mit dem Ziel, die Kontrolle zu 盲ndern oder zu beeinflussen.
FAQ
What stake in Enlivex Therapeutics (ENLV) do Armistice Capital and Steven Boyd report?
Does the filing state Armistice Capital intends to influence control of Enlivex (ENLV)?
Who directly holds the reported Enlivex shares?
What voting and dispositive powers are reported for the shares?
When was this Schedule 13G/A signed?
